Table II.
1–2 grade adverse events | 3–4 grade adverse events | |||
---|---|---|---|---|
Non-hematological toxicity | Number, n | Percentage (n=205) | Number, n | Percentage (n=205) |
Polyneuropathy | ||||
Grade 1 | 36 | 17.6 | 10 | 4.9 |
Grade 2 | 45 | 33.0 | ||
Infections | 8 | 4.0 | 2 | 1.0 |
Thrombosis | 7 | 3.4 | 1 | 0.5 |
Pulmonary embolism | – | – | 2 | 1.0 |
Constipation | 2 | 1.0 | – | – |
Skin alterations | 2 | 1.0 | 3 | 1.5 |
VTD, bortezomib, thalidomide, dexamethasone.